Darzalex Faspro
These highlights do not include all the information needed to use DARZALEX FASPRO safely and effectively. See full prescribing information for DARZALEX FASPRO. DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use Initial U.S. Approval: 2020
4bb241af-4299-4373-8762-2d6709515db0
HUMAN PRESCRIPTION DRUG LABEL
Nov 28, 2023
Janssen Biotech, Inc.
DUNS: 099091753
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
daratumumab and hyaluronidase-fihj (human recombinant)
Product Details
FDA regulatory identification and product classification information